These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 24315317)
61. Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy. Saeed LH; Mayet AY Int J Med Sci; 2013; 10(11):1497-502. PubMed ID: 24046523 [TBL] [Abstract][Full Text] [Related]
62. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168 [TBL] [Abstract][Full Text] [Related]
63. Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. Zalloum I; Hakooz N; Arafat T Mol Biol Rep; 2012 Apr; 39(4):4195-200. PubMed ID: 21769476 [TBL] [Abstract][Full Text] [Related]
64. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294 [TBL] [Abstract][Full Text] [Related]
65. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Dandara C; Lombard Z; Du Plooy I; McLellan T; Norris SA; Ramsay M Pharmacogenomics; 2011 Dec; 12(12):1663-70. PubMed ID: 22118051 [TBL] [Abstract][Full Text] [Related]
66. Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents. Park JJ; Park KW; Kang J; Jeon KH; Kang SH; Ahn HS; Han JK; Koh JS; Lee SE; Yang HM; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS Int J Cardiol; 2013 Feb; 163(1):79-86. PubMed ID: 23260377 [TBL] [Abstract][Full Text] [Related]
67. Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers. Ellison CA; Abou El-Ella SS; Tawfik M; Lein PJ; Olson JR J Toxicol Environ Health A; 2012; 75(4):232-41. PubMed ID: 22352331 [TBL] [Abstract][Full Text] [Related]
68. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Zuo J; Xia D; Jia L; Guo T Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523 [TBL] [Abstract][Full Text] [Related]
69. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Sorich MJ; Rowland A; McKinnon RA; Wiese MD Circ Cardiovasc Genet; 2014 Dec; 7(6):895-902. PubMed ID: 25258374 [TBL] [Abstract][Full Text] [Related]
70. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435 [TBL] [Abstract][Full Text] [Related]
71. Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention. Liu Y; Liu N; Li W; Shao H; Zhi H; Li J Pharmacology; 2013; 91(3-4):165-72. PubMed ID: 23429358 [TBL] [Abstract][Full Text] [Related]
72. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Kaneko A; Lum JK; Yaviong L; Takahashi N; Ishizaki T; Bertilsson L; Kobayakawa T; Björkman A Pharmacogenetics; 1999 Oct; 9(5):581-90. PubMed ID: 10591538 [TBL] [Abstract][Full Text] [Related]
74. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494 [TBL] [Abstract][Full Text] [Related]
75. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population. Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224 [TBL] [Abstract][Full Text] [Related]
77. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Scott SA; Martis S; Peter I; Kasai Y; Kornreich R; Desnick RJ Pharmacogenomics J; 2012 Aug; 12(4):297-305. PubMed ID: 21358751 [TBL] [Abstract][Full Text] [Related]
78. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. Holmes MV; Perel P; Shah T; Hingorani AD; Casas JP JAMA; 2011 Dec; 306(24):2704-14. PubMed ID: 22203539 [TBL] [Abstract][Full Text] [Related]
79. Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips. Nakamoto K; Kidd JR; Jenison RD; Klaassen CD; Wan YJ; Kidd KK; Zhong XB Pharmacogenet Genomics; 2007 Feb; 17(2):103-14. PubMed ID: 17301690 [TBL] [Abstract][Full Text] [Related]
80. Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease. Ma L; Yuan Y; Li J; Yu C; Zhao J Int J Immunogenet; 2020 Dec; 47(6):539-545. PubMed ID: 32862511 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]